Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer

BACKGROUND: The mammalian target of rapamycin inhibitor everolimus is approved as an antitumor agent in advanced estrogen receptor-positive breast cancer. Surrogate bone marker data from clinical trials suggest effects on bone metabolism, but the mode of action of everolimus in bone biology remains...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Breast Cancer Res
Main Authors: Browne, Andrew J., Kubasch, Marie L., Göbel, Andy, Hadji, Peyman, Chen, David, Rauner, Martina, Stölzel, Friedrich, Hofbauer, Lorenz C., Rachner, Tilman D.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2017
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5551016/
https://ncbi.nlm.nih.gov/pubmed/28793923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0885-7
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker